Key takeaways
Nausea is the most common side effect of tirzepatide (Mounjaro, Zepbound).
In clinical trials of Mounjaro and Zepbound, 12%–29% of people reported nausea.
Tirzepatide may cause nausea because it slows digestion and makes you feel fuller faster.
Avoiding triggers (e.g. greasy foods) and eating smaller, more frequent meals can help reduce tirzepatide nausea. Your healthcare provider may also recommend lowering your dose or taking anti-nausea medication.
Here's what we'll cover
Here's what we'll cover
Here's what we'll cover
Key takeaways
Nausea is the most common side effect of tirzepatide (Mounjaro, Zepbound).
In clinical trials of Mounjaro and Zepbound, 12%–29% of people reported nausea.
Tirzepatide may cause nausea because it slows digestion and makes you feel fuller faster.
Avoiding triggers (e.g. greasy foods) and eating smaller, more frequent meals can help reduce tirzepatide nausea. Your healthcare provider may also recommend lowering your dose or taking anti-nausea medication.
Tirzepatide, the active ingredient in Zepbound and Mounjaro, is largely considered a rockstar treatment for weight loss and type 2 diabetes. But for all its positives (of which there are a lot, BTW), the drug does come with some negatives, such as nausea.
In clinical trials, 12%--18% of people taking Mounjaro and 25%--29% of people taking Zepbound reported nausea. Translation: Nausea is the most common side effect of tirzepatide. But you can get rid of it with a few simple strategies, such as eating smaller meals more frequently, avoiding trigger foods and drinks, and staying hydrated.
Ahead, we break down what causes tirzepatide nausea and offer research-backed tips to get relief.
Why does tirzepatide cause nausea?
It’s unclear exactly why tirzepatide can cause nausea. However, there are some theories — many (if not all) of which have to do with how the drug works.
As a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide affects the digestive system in several ways. While these gastrointestinal (GI) effects can help regulate blood sugar and promote weight loss, they can also lead to nausea.
Here’s a closer look at the reasons why tirzepatide can cause nausea.
1. Slowed digestion
Tirzepatide delays gastric emptying, i.e. the rate at which food moves through your gut. Essentially, food lingers in your stomach and moves from your tum into the small intestine more gradually.
This can help you feel fuller longer and stabilize blood sugar. But it can also lead to nausea in addition to other side effects, such as vomiting, bloating, and abdominal pain.
2. Increased feeling of fullness
As mentioned, tirzepatide can make you feel fuller longer by delaying gastric emptying or keeping food in the stomach for longer. But it can also increase satiety (i.e. fullness) by acting on the areas of the brain that regulate appetite. Together, these effects can contribute to nausea.
When food stays in your stomach longer and your appetite is reduced, it’s easier to feel uncomfortably full — especially at the beginning of treatment or when your dose increases.
That's because it can take some time to figure out the right portion sizes on tirzepatide. You’ll likely need less food than you did pre-treatment to feel satisfied. So, if you eat your usual amount, you may become too full and, in turn, nauseated.
3. Activation of central nervous system receptors
Tirzepatide doesn’t just act on the stomach and small intestine — it also acts on the nervous system. The GLP-1 and GIP receptors in the brain are thought to be involved in appetite control, among other functions.
Activation of GLP-1 receptors in the central nervous system may cause a nausea response. However, this theory is mainly based on findings from some animal models.
8 ways to get relief from tirzepatide nausea
Nearly 15% of people taking tirzepatide or semaglutide, another GLP-1 medication, for obesity discontinue the treatment due to side effects like nausea. However, there’s some good news: GI side effects from tirzepatide are usually mild to moderate in severity and decrease over time.
Still, there are several practical ways to reduce nausea on tirzepatide and get relief. Here’s what the research suggests.
1. Stick to your dose escalation schedule
Medications containing tirzepatide come in multiple dosage strengths. For example, Zepbound dosages range from 2.5 mg to 15 mg. Each medication also comes with a dose escalation schedule. The medication is typically started at a low dose, which is gradually increased every four weeks or so.
While side effects could occur at any dose, they’re more common at higher strengths. If you’re experiencing nausea after increasing your dose, it may be worth having a discussion with your healthcare provider about titrating back down.
Not everyone’s maintenance dose (i.e. the dosage strength that marries effectiveness and tolerability) is the same. You may find that you fare better on a lower dose than the highest recommended dose.
2. Eat smaller, more frequent meals
Tirzepatide slows digestion and increases feelings of fullness. So, eating larger portions (such as those you ate pre-treatment) can cause you to get uncomfortably full, fast. Sound familiar? Then consider eating smaller meals more often during the day. For example, splitting three meals a day into four or more.
This tactic can help you get your fill of essential nutrients without becoming overly full and nauseated. Just remember to pack your plate (even if it’s a small one) with fiber, protein, and other tirzepatide-friendly foods.
3. Avoid trigger foods and drinks
Honing your dietary habits to tirzepatide nausea relief may also include avoiding foods known to trigger symptoms. When you’re nauseated, experts generally recommend avoiding the following foods and drinks:
Greasy, processed foods (e.g. sausages, fast-food burgers, fried foods)
High-sodium (salty) foods (e.g. chips, packaged snacks and foods)
Foods with strong smells
Caffeine, alcohol, and carbonated drinks
Very spicy foods
Dairy products
4. Stay hydrated
When your nausea leads to vomiting, it can have some serious consequences, such as dehydration. Therefore, increased fluid intake is recommended to offset the loss.
The target daily intake for water is about 7 cups (1,600 mL) on average, for adults. Keep in mind that if you’re nauseated, you’ll want to sip on fluids slowly and avoid drinking them with a straw.
Drinking plenty of water is always important, but you can also hydrate with water-rich foods, such as soup, yogurt, and gelatin.
5. Opt for bland, easily digestible food
We’ve discussed foods to avoid when you’re feeling nauseous, but what should you eat instead? A balanced, nutrient-rich diet is always a good idea, but certain food choices may be best suited for nausea relief.
Take a bland diet, for example. Bland foods are easy to digest, giving the GI tract a rest when it’s been stressed. These include foods that are soft, low in fiber, cooked, and/or not spicy. Here are some examples of bland foods:
Broth
Tofu
Lean meat, such as skinless chicken and fish
Vegetables, such as beets, carrots, and spinach
Taking it a step further, a BRAT diet may also help alleviate nausea and vomiting. This includes:
6. Avoid lying down or exercising after eating
When you eat, food moves down the esophagus and through the GI tract. It gets a little help from gravity, which is why it’s recommended to stop eating several hours before going to bed.
Similarly, lying down or reclining after eating allows stomach acid and undigested food to flow in the wrong direction — back the way it came. So, try to remain upright after eating as well as eating too close to bedtime.
However, this doesn’t mean you should participate in strenuous activities after eating. Your GI tract needs blood flow to function properly. But when you exercise, those working muscles need blood flow too.
Give your food a chance to settle before getting active. At most, you might consider a light walk after meals, which has been shown to improve GI symptoms like nausea.
7. Look into anti-nausea medication
When other remedies aren’t helping, it may be time to look into anti-nausea medication. There are both over-the-counter (OTC) and prescription options available, though you should first check in with your healthcare provider to see what they recommend.
You can find OTC options like bismuth subsalicylate (Pepto Bismol) and dimenhydrinate (Dramamine) at most pharmacies. Talk to your provider to see if you’re a good candidate for prescription options, such as ondansetron (Zofran).
These medicines usually offer relief fairly quickly — within 30–60 minutes after taking them.
8. Consider tirzepatide alternatives
Tirzepatide is just one weight loss medication of many. While other, alternative drugs can also cause nausea, they may be more tolerable for you. Research generally suggests that the risk of nausea is less with other GLP-1 medications, such as semaglutide (the active ingredient in Ozempic and Wegovy).
If you find that your tirzepatide nausea isn’t letting up, ask your healthcare provider if switching to a different medication is an option. In addition to tirzepatide and semaglutide, liraglutide (Saxenda) is another GLP-1 medication to know.
When to see a healthcare provider about tirzepatide nausea
Severe symptoms or those that won’t go away can warrant medical attention, and severe or persistent nausea is no different. If your tirzepatide nausea isn’t improving, it’s wise to let your healthcare provider know.
You should also seek care if you experience any of the following on tirzepatide:
Signs of pancreatitis, such as severe abdominal pain
Stomach pain that radiates to your back
Signs of an allergic reaction, such as swelling of the throat and trouble swallowing
Other GI symptoms that won’t go away, such as vomiting, diarrhea, and upset stomach
Depending on your situation, your healthcare provider might recommend:
Lowering your dose. Nausea on tirzepatide is more common at higher strengths. So, titrating down to a lower strength may help. While the medication is generally increased over time, some people find that a lower "maintenance dose” is still effective while curbing side effects.
Staying on your current dose. Mild tirzepatide nausea generally goes away or improves on its own. You may just need more time for your body to adjust to the medication. Increasing your dose could also come with more nausea, which is why your provider may prefer for you to stay where you’re at for longer.
Anti-nausea medication. If your other efforts to reduce nausea haven’t panned out, it may be time for some anti-nausea medicine. Your healthcare provider might recommend starting with an OTC option (e.g. Pepto Bismol) or go straight to prescribing an Rx treatment (e.g. ondansetron). It all depends on the severity of your symptoms and other individual factors.
Switching medications. Tirzepatide is more likely to cause nausea than other similar medications (e.g. semaglutide). So, your prescriber may recommend switching to a different medication that you may tolerate better.
Bottom line
Tirzepatide nausea is common, but that doesn’t make the discomfort any easier. Fortunately, there are some ways to manage this side effect. Keep the following in mind as you navigate nausea while taking tirzepatide:
Roughly one in five people taking tirzepatide will experience nausea. It’s the most common side effect of this medication. Fortunately, it’s usually mild and subsides as your body adjusts.
The exact reason why tirzepatide can cause nausea isn’t fully understood. It’s usually chalked up to how the medication affects digestion.
At-home remedies may help you navigate this and other GI side effects. These include eating bland foods, avoiding trigger foods and drinks, and sticking to smaller, more frequent meals.
Let your healthcare provider know if tirzepatide nausea isn’t improving. They may recommend adjusting your dose, trying anti-nausea medication, or switching to a different medication.
Frequently asked questions (FAQs)
How long does tirzepatide nausea last?
Though they’re usually mild and temporary, GI side effects on tirzepatide mainly occur when starting the medication and during dose escalation. The general dose escalation schedule for medications containing tirzepatide is every four weeks until the maintenance (or maximum) dose is achieved.
This schedule could span several months, but that doesn’t mean you’ll have nausea the entire time. Your nausea may subside within days or weeks of adjusting to your current dose, then flare up again if and when you move up a dose.
How to prevent nausea on tirzepatide?
Tirzepatide nausea is often manageable, but it may not be completely preventable. However, you can try implementing the general recommendations in anticipation of it:
Eat bland food or try the BRAT diet to give your digestive tract a rest
Avoid foods that trigger nausea, such as greasy foods, caffeine, and dairy products
Get plenty of fluids to avoid dehydration
Eat smaller, more frequent meals in acknowledgement of slower stomach emptying
Should I stop tirzepatide if I’m nauseous?
Mild nausea isn’t usually a reason to stop taking tirzepatide. Tirzepatide nausea is typically a temporary side effect and often manageable with a few adjustments to your routine. However, if your nausea becomes too much, let your healthcare provider know what’s going on. They may recommend stopping the medication in favor of another.
What foods help with tirzepatide nausea?
Bland foods may help with tirzepatide nausea because they’re easy to digest. This can include soft or cooked foods like tofu, eggs, and bland vegetables. A BRAT diet consisting of bananas, rice, applesauce, and toast can also help give your GI tract a bit of a break.
DISCLAIMER
If you have any medical questions or concerns, please talk to your healthcare provider. The articles on Health Guide are underpinned by peer-reviewed research and information drawn from medical societies and governmental agencies. However, they are not a substitute for professional medical advice, diagnosis, or treatment.
Zepbound Important Safety Information: Read more about serious warnings and safety info.
Mounjaro Important Safety Information: Read more about serious warnings and safety info.
GLP-1 Important Safety Information: Read more about serious warnings and safety info.
Ozempic Important Safety Information: Read more about serious warnings and safety info.
Wegovy Important Safety Information: Read more about serious warnings and safety info.
Saxenda Important Safety Information: Read more about serious warnings and safety info.
References
Brinkman, J. E., Dorius, B., & Sharma, S. (2023). Physiology, body fluids. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK482447/
Colorado, M., Gomez Miranda, J., & Arias-Morales, C. E. (2025). Unanticipated adverse events with tirzepatide: Three cases underscoring the importance of postmarketing monitoring. JCEM Case Reports, 3(10), luaf195. doi: 10.1210/jcemcr/luaf195. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12395549/
Farzam, K. & Patel, P. (2024). Tirzepatide. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK585056/
Fisman, E. Z. & Tenenbaum, A. (2021). The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovascular Diabetology, 20(1), 225. doi: 10.1186/s12933-021-01412-5. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8613929/
Gasoyan, H., Butsch, W. S., Casacchia, N. J., et al. (2025). Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice. Obesity (Silver Spring, Md.), 33(12), 2296–2303. doi: 10.1002/oby.70058. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12636059/
Ghaleb, J., Khouzami, K. K., Nassif, N., et al. (2025). Unveiling tirzepatide's therapeutic spectrum: A dual GIP/GLP-1 agonist targeting metabolic, neurological, and cardiovascular health. International Journal of Endocrinology, 2025, 2876156. doi: 10.1155/ije/2876156. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12507501/
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., et al. (2022). Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: A multidisciplinary expert consensus. Journal of Clinical Medicine, 12(1), 145. doi: 10.3390/jcm12010145. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9821052/
Hosseini-Asl, M. K., Taherifard, E., & Mousavi, M. R. (2021). The effect of a short-term physical activity after meals on gastrointestinal symptoms in individuals with functional abdominal bloating: a randomized clinical trial. Gastroenterology and Hepatology From Bed to Bench, 14(1), 59–66. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8035544/
Jalleh, R. J., Plummer, M. P., Marathe, C. S., et al. (2024). Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. The Journal of Clinical Endocrinology and Metabolism, 110(1), 1–15. doi: 10.1210/clinem/dgae719. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11651700/
Karrar, H. R., Nouh, M. I., Nouh, Y. I., et al. (2023). Tirzepatide-induced gastrointestinal manifestations: A systematic review and meta-analysis. Cureus, 15(9), e46091. doi: 10.7759/cureus.46091. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC10614464/
Khawaji, A., A Jaly, A., A Bakri, H., et al. (2025). Weight loss efficacy of tirzepatide compared to placebo or GLP-1 receptor agonists in adults with obesity or overweight: A meta-analysis of randomized controlled trials with ≥ 20 weeks treatment duration. Journal of Obesity, 2025, 3442754. doi: 10.1155/jobe/3442754. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12313391/
MedlinePlus. (2025). Tirzepatide injection. Retrieved from https://medlineplus.gov/druginfo/meds/a622044.html
MedlinePlus. (2024). When you have nausea and vomiting. Retrieved from https://medlineplus.gov/ency/patientinstructions/000122.htm
Mishra, R., Raj, R., Elshimy, G., et al. (2023). Adverse events related to tirzepatide. Journal of the Endocrine Society, 7(4), bvad016. doi: 10.1210/jendso/bvad016. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9915969/
O'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025). Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy. Progress in Cardiovascular Diseases, 89, 102–112. doi: 10.1016/j.pcad.2024.12.010. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12103286/
Rubino, D. M., Pedersen, S. D., Connery, L., et al. (2025). Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes, Obesity & Metabolism, 27(4), 1826–1835. doi: 10.1111/dom.16176. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11885085/
Taylor, K. & Tripathi, A. K. (2025). Adult dehydration. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK555956/
U.S. Food and Drug Administration (FDA-a). (2025). Mounjaro (tirzepatide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
U.S. Food and Drug Administration (FDA-b). (2025). Zepbound (tirzepatide) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf
Weir, S. B. S. & Akhondi, H. (2023). Bland diet. StatPearls. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK538142/
Wharton, S., Calanna, S., Davies, M., et al. (2021). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity & Metabolism, 24(1), 94–105. doi: 10.1111/dom.14551. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC9293236/
Wharton, S., Davies, M., Dicker, D., et al. (2022). Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgraduate Medicine, 134(1), 14–19. doi: 10.1080/00325481.2021.2002616. Retrieved from: https://www.tandfonline.com/doi/full/10.1080/00325481.2021.2002616













